Showing 4981-4990 of 21485 results for "".
- Teoxane Launches RHA Topical Skin Booster for Post-Microneedling Usehttps://reachmd.com/news/teoxane-launches-rha-topical-skin-booster-for-post-microneedling-use/2488074/Teoxane has launched RHA Topical Skin Booster, a professional-use sterile topical solution developed for application immediately following microneedling procedures. The product expands the company’s Resilient Hyaluronic Acid (RHA) technology beyond its injectable portfolio and into procedu
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://reachmd.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- Allergan Aesthetics Updates Practice Loyalty Program With New Growth Benefitshttps://reachmd.com/news/allergan-aesthetics-updates-practice-loyalty-program-with-new-growth-benefits/2488065/Allergan Aesthetics, an AbbVie company, announced updates to its Allergan Partner Privileges (APP) customer portfolio loyalty program for aesthetics practices, with changes focused on pricing and benefit transparency as well as rewards tied to portfolio growth.
- SEER-22 Study Finds Mycosis Fungoides Survival Gapshttps://reachmd.com/news/seer-22-mycosis-fungoides-survival-gaps/2488058/Key Takeaways In a U.S. SEER-22 cohort of 13,694 patients with mycosis fungoides, 5-year overall survival was 85.8%, with lower estimates in Black and American Indian/Alaska Native patients and the highest estimate in Asian/Pacific Islander patients. After adjustment
- New Photoimmunotherapy Approach Targets T Cells and Tumor Antigenshttps://reachmd.com/news/study-new-photoimmunotherapy-approach-targets-t-cells-and-tumor-antigens/2488067/A new activatable photoimmunotherapy platform may enable more selective depletion of pathogenic cells while limiting inflammatory effects associated with existing PIT approaches, according to new research. Photoimmunotherapy
- Study: Reddit Upvotes May Not Reflect Quality of Rosacea Advicehttps://reachmd.com/news/study-reddit-upvotes-may-not-reflect-quality-of-rosacea-advice/2488056/A study of Reddit’s r/Rosacea community examined what users discuss and whether engagement differed according to how closely recommendations aligned with National Rosacea Society (NRS) standard management options. Treatment Experiences Dominate Rosacea Discussions Investigators an
- CKD-Associated Pruritus Affects 16.3% on Hemodialysishttps://reachmd.com/news/ckd-associated-pruritus-affects-163-on-hemodialysis/2488050/Key Takeaways Among 294 eligible adults receiving maintenance haemodialysis at three dialysis centers affiliated with Başkent University Ankara Hospital in Turkey—after excluding patients with active dermatologic, hepatic or other systemic, malignant, infectious, or other acu
- FTH1 Loss Exposes Liver-Specific PDAC Metastasis Vulnerabilityhttps://reachmd.com/news/fth1-loss-liver-specific-pdac-metastasis-vulnerability/2488046/Key Takeaways In preclinical pancreatic ductal adenocarcinoma (PDAC) liver metastasis models, ferritin heavy chain (FTH1) emerged as a liver-specific dependency, and its loss suppressed liver metastatic growth while sparing the other tested growth settings. The contr
- MetS-OA Linked to More RTKA Complications and Chargeshttps://reachmd.com/news/mets-oa-rtka-complications-charges/2488045/Key Takeaways Among more than 1.3 million U.S. revision total knee arthroplasty hospitalizations, 16.1% met the study definition of metabolic syndrome-associated osteoarthritis (MetS-OA), and that share increased over the study period. The MetS-OA group had a heavier
- Abrocitinib Responses Maintained Through Week 72 in JADE REALhttps://reachmd.com/news/abrocitinib-responses-maintained-through-week-72-in-jade-real/2488053/New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD). Researchers for the JADE REAL trial enrolled 312 patients